MT
Metagen Therapeutics
Japan · Biotech
A clinical-stage biotechnology company developing microbiome-based therapies using fecal microbiota transplantation.
Developing microbiota-based medicines
Metagen Therapeutics uses a donor microbiota bank as the foundation for drug development and medical services. Fecal microbiota transplantation transfers microorganisms from healthy donors with the aim of rebuilding the recipient's intestinal microbial community.
Its oral FMT drug programme for ulcerative colitis is in Phase 1/2 clinical trials in Japan and the United States. The company, headquartered in Tsuruoka, also works on applications in cancer and central nervous system disease.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series B extension (first close) | ¥190M | Hokkaido University Green Frontier Fund No. 1 Investment Limited Partnership — ParticipantTokai Research and Development No. 1 Investment Limited Partnership — Participant |